TETRA BIO-PHARMA
Global Leaders in Cannabinoid-Based Drug Discovery and Development
Value Creating Milestones
December 30, 2020
Value Creating Milestones
2020 - Milestone Status
ARDS-003
- Completion of intravenous finished drug product for human trials.
- Completed; NR dated August 18th.
- Completion of clinical batch IND-enabling toxicology with no safety issues for proceeding to humans.
- Completed; Nov 16th & Dec 2nd NR.
- File CTA/IND of Phase 1 trial.
- Initiated regulatory process.
QIXLEEF
- Initiate PLENITUDE (Phase II) in advanced cancer patients with uncontrolled pain in USA.
- Trial launched; NR dated Sept 2nd.
- File EU Phase 3 Plenitude trial in cancer pain.
- Trial implementation; NR dated Nov 16th.
Ophthalmic
- File CTA/IND of Phase 1 trial
- Initiated regulatory process.
CAUMZ
- Initiate Phase 3 enabling toxicology.
- Studies initiated.
- File IND THC-CBD interactions trials required for NDA.
- Initiated regulatory process.
- File IND for Reborn trial.
- Refer to Nov. 16th NR.
- File IND for trial in advanced cancer patients.
Initiated regulatory process.
QIXLEEF & CAUMZ:
- Complete mapping of cannabinoid metabolites
- Completed; Nov 16th NR.
Dronabinol NDS filing
- New Drug Submission filing to Health Canada
- Completed; Dec 30th NR.
Corporate Presentation I
This is an excerpt of the original content. To continue reading it, access the original document here.
Attachments
- Original document
- Permalink
Disclaimer
Tetra Bio-Pharma Inc. published this content on 30 December 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 05 January 2021 15:51:07 UTC